Received: 28 July 2019
Accepted: 31 July 2019
First Online: 14 September 2019
Duality of interest
: SEI has served on clinical trial steering or executive committees for Eisai (through the Thrombolysis in Myocardial Infarction [TIMI] Study Group) and AstraZeneca, which have examined diabetes prevention through weight loss or glucose lowering medications. The other authors declare no dualities of interest associated with their contribution to this manuscript.
Free to read: This content has been made available to all.